Barclays raised the firm’s price target on Stryker to $341 from $335 and keeps an Overweight rating on the shares. The firm says that after a strong quarter for MedSurg and robot sales, it is taking estimates higher, reflecting increased confidence in the “super cycle” and the demand for robotic surgery systems and enabling technology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SYK: